VNDA
HEALTHCAREVanda Pharmaceuticals Inc
AI Insight
What's Moving VNDA Today?
No stock-specific AI insight has been generated for VNDA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$4.14$9.94
$5.95
Fundamentals
Market Cap$361M
P/E Ratio—
EPS$-4.06
Dividend Yield—
Dividend / Share—
ROE-60.5%
Profit Margin-110.0%
Debt / Equity—
Trading
Volume585K
Avg Volume (10D)—
Shares Outstanding60.1M
VNDA News
20 articles- Insomnia Market Witnesses Robust Growth During the Forecast Period (2026-2036) with Emerging Orexin Receptor Antagonists and Melatonin Receptor Agonist | DelveInsightYahoo Finance·Jun 18, 2026
- Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular PsoriasisYahoo Finance·May 27, 2026
- Charcot-Marie-Tooth Disease Market Growth to Accelerate Significantly During the Forecast Period (2026-2036) Driven by the Launch of Emerging Disease-Modifying Therapies | DelveInsightYahoo Finance·May 21, 2026
- How The Vanda Pharmaceuticals (VNDA) Investment Story Is Shifting With BYSANTI And NereusYahoo Finance·May 18, 2026
- Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026?Yahoo Finance·May 10, 2026
- Vanda Pharmaceuticals Announces Participation at May 2026 Investor ConferencesBioSpace·May 8, 2026
- Vanda Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- Vanda Pharmaceuticals Inc. Q1 2026 Earnings Call SummaryMoby·May 7, 2026
- Vanda (VNDA) Q1 2026 Earnings Call TranscriptMotley Fool·May 6, 2026
- Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 6, 2026
- Vanda Pharmaceuticals Reports First Quarter 2026 Financial ResultsYahoo Finance·May 6, 2026
- Wall Street Analysts Predict a 105.03% Upside in Vanda (VNDA): Here's What You Should KnowYahoo Finance·May 5, 2026
- Model N Appoints Thomas Gibbs to Board of DirectorsYahoo Finance·May 5, 2026
- Sector Update: Health Care Stocks Softer in Afternoon TradingYahoo Finance·May 4, 2026
- Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 YearsYahoo Finance·May 4, 2026
- Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026Yahoo Finance·Apr 29, 2026
- Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM EvidenceYahoo Finance·Apr 28, 2026
- Incyte (INCY) Beats Q1 Earnings and Revenue EstimatesYahoo Finance·Apr 28, 2026
- Geron Corporation (GERN) Appoints Timothy Williams as EVP, Chief Legal OfficerYahoo Finance·Apr 25, 2026
- Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of DirectorsYahoo Finance·Apr 22, 2026
All 20 articles loaded
Price Data
Open$5.97
Previous Close$6.00
Day High$6.11
Day Low$5.93
52 Week High$9.94
52 Week Low$4.14
52-Week Range
$4.14$9.94
$5.95
Fundamentals
Market Cap$361M
P/E Ratio—
EPS$-4.06
Dividend Yield—
Dividend / Share—
ROE-60.5%
Profit Margin-110.0%
Debt / Equity—
Trading
Volume585K
Avg Volume (10D)—
Shares Outstanding60.1M
About Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company is headquartered in Washington, the District of Columbia.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—